↓ Skip to main content

Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants

Overview of attention for article published in Cochrane database of systematic reviews, July 2010
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
170 Dimensions

Readers on

mendeley
144 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants
Published in
Cochrane database of systematic reviews, July 2010
DOI 10.1002/14651858.cd000174.pub2
Pubmed ID
Authors

Peter W Fowlie, Peter G Davis, William McGuire

Abstract

Persistent patent ductus arteriosus (PDA) is associated with mortality and morbidity in preterm infants. Prostaglandin synthetase inhibitors such as indomethacin promote PDA closure but also have potential side effects. The effect of the prophylactic use of indomethacin, where infants who may not have gone on to develop a symptomatic PDA would be exposed to indomethacin, warrants particular scrutiny. To determine the effect of prophylactic indomethacin on mortality and morbidity in preterm infants. The standard search strategy of the Cochrane Neonatal Review Group was used. This included searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 5, 2010), MEDLINE, EMBASE and CINAHL (until April 2010), conference proceedings, and previous reviews. Randomised or quasi-randomised controlled trials that compared prophylactic indomethacin versus placebo or no drug in preterm infants. The standard methods of the Cochrane Neonatal Review Group were used, with separate evaluation of trial quality and data extraction by two review authors. Nineteen eligible trials in which 2872 infants participated were identified. Most participants were very low birth weight, but the largest single trial restricted participation to extremely low birth weight infants (N = 1202). The trials were generally of good quality.The incidence of symptomatic PDA [typical relative risk (RR) 0.44, 95% confidence interval (CI) 0.38 to 0.50] and PDA surgical ligation (typical RR 0.51, 95% CI 0.37,0.71) was significantly lower in treated infants. Prophylactic indomethacin also significantly reduced the incidence of severe intraventricular haemorrhage (typical RR 0.66, 95% CI 0.53 to 0.82). Meta-analyses found no evidence of an effect on mortality (typical RR 0.96, 95% CI 0.81 to 1.12) or on a composite of death or severe neurodevelopmental disability assessed at 18 to 36 months old (typical RR 1.02, 95% CI 0.90, 1.15). Prophylactic indomethacin has short-term benefits for preterm infants including a reduction in the incidence of symptomatic PDA, PDA surgical ligation, and severe intraventricular haemorrhage. However, there is no evidence of effect on mortality or neurodevelopment.

Mendeley readers

The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ethiopia 1 <1%
South Africa 1 <1%
United Kingdom 1 <1%
Brazil 1 <1%
United States 1 <1%
Unknown 139 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 21 15%
Student > Master 20 14%
Student > Bachelor 17 12%
Researcher 16 11%
Student > Postgraduate 14 10%
Other 55 38%
Unknown 1 <1%
Readers by discipline Count As %
Medicine and Dentistry 90 63%
Unspecified 19 13%
Nursing and Health Professions 8 6%
Social Sciences 6 4%
Psychology 4 3%
Other 16 11%
Unknown 1 <1%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2014.
All research outputs
#3,639,773
of 12,527,093 outputs
Outputs from Cochrane database of systematic reviews
#5,990
of 8,923 outputs
Outputs of similar age
#78,329
of 272,397 outputs
Outputs of similar age from Cochrane database of systematic reviews
#156
of 224 outputs
Altmetric has tracked 12,527,093 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,397 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 224 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.